Latest Stocks: Gilead Sciences, Inc. (GILD) Stake Decreased by Sit Investment Associates Inc.

Latest Stocks: Gilead Sciences, Inc. (GILD) Stake Decreased by Sit Investment Associates Inc.

Sit Investment Associates Inc. cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 44.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 110,225 shares of the biopharmaceutical company’s stock after selling 87,255 shares during the period. Sit Investment Associates Inc.’s holdings in Gilead Sciences were worth $7,486,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. increased its position in Gilead Sciences by 29.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 2,148,192 shares of the biopharmaceutical company’s stock valued at $169,965,000 after buying an additional 489,155 shares in the last quarter. MUFG Securities EMEA plc increased its position in Gilead Sciences by 0.8% in the third quarter. MUFG Securities EMEA plc now owns 9,746 shares of the biopharmaceutical company’s stock valued at $771,000 after buying an additional 76 shares in the last quarter. Lombard Odier Transatlantic Limited Partnership increased its position in Gilead Sciences by 55.6% in the third quarter. Lombard Odier Transatlantic Limited Partnership now owns 1,400 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 500 shares in the last quarter. Compagnie Lombard Odier SCmA increased its position in Gilead Sciences by 14.0% in the third quarter. Compagnie Lombard Odier SCmA now owns 837,669 shares of the biopharmaceutical company’s stock valued at $66,293,000 after buying an additional 103,044 shares in the last quarter. Finally, AMP Capital Investors Ltd increased its position in Gilead Sciences by 5.6% in the third quarter. AMP Capital Investors Ltd now owns 830,692 shares of the biopharmaceutical company’s stock valued at $64,676,000 after buying an additional 43,819 shares in the last quarter. 74.19% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences, Inc. (NASDAQ GILD) opened at 65.48 on Tuesday. The company has a market capitalization of $85.56 billion, a PE ratio of 6.92 and a beta of 1.11. The firm’s 50-day moving average price is $66.19 and its 200 day moving average price is $69.73. Gilead Sciences, Inc. has a 52 week low of $63.88 and a 52 week high of $88.85.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.18 by $0.02. Gilead Sciences had a return on equity of 92.36% and a net margin of 44.43%. The business had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.66 billion. Equities research analysts expect that Gilead Sciences, Inc. will post $8.21 earnings per share for the current fiscal year.

Several research firms have recently issued reports on GILD. Royal Bank of Canada lowered their price objective on Gilead Sciences to $75.00 in a research note on Wednesday, February 8th. Jefferies Group LLC lowered their price objective on Gilead Sciences from $83.00 to $83.00 and set a “neutral” rating for the company in a research note on Wednesday, February 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 8th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $95.00 price objective (down previously from $102.00) on shares of Gilead Sciences in a research note on Wednesday, February 8th. Finally, Robert W. Baird reaffirmed an “outperform” rating and issued a $87.00 price objective on shares of Gilead Sciences in a research note on Wednesday, February 8th. Twelve analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. Gilead Sciences presently has an average rating of “Buy” and a consensus price target of $80.61. In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $67.18, for a total value of $4,926,510.94. Following the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at $214,973,917.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John Francis Cogan sold 9,943 shares of the business’s stock in a transaction on Tuesday, May 9th. The stock was sold at an average price of $67.25, for a total value of $668,666.75. Following the completion of the sale, the director now directly owns 47,562 shares in the company, valued at $3,198,544.50. The disclosure for this sale can be found here. Insiders sold 88,276 shares of company stock worth $5,932,578 over the last three months. Corporate insiders own 1.40% of the company’s stock.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Related posts

Leave a Comment